Skip to content

Study Details

Testing Efzofitimod for Adults with Systemic Sclerosis Related Interstitial Lung Disease

(IRB#: IRB_00171090)

Systemic Sclerosis (hardening or tightening of the skin)-Related Interstitial Lung Disease is a rare disease that leads to severe health conditions. This study will test a drug called Efzofitimod to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with Efzofitimod or a placebo. A placebo looks like the study drug but does not have the medication. The drug and placebo are taken as a liquid given under the skin. Being in the study will require 9 study visits at the clinic and last up to 32 weeks. Medical tests will be done during the study to track the health of participants. People will be paid for being in the study.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 and older
  • Diagnosis of Systemic Sclerosis
  • Sclerosis on the arms, legs, neck, and face at the beginning of study participation
  • Current specific conditions of Systemic Sclerosis-Related Interstitial Lung Disease
  • Attend in person at the study clinic

Exclusion Criteria

  • Current heavy smoker
  • Current substance abuse or history of alcohol and drug abuse, within the prior year of participation
  • Major surgery 8 weeks before or planned 12 months before study participation
  • Other specific health conditions
  • Pregnant or breastfeeding

Will I be paid for my time?


For more information contact:

Chloe Kirkpatrick


IRB#: IRB_00171090

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2024-02-07 07:00:00

Specialties: Pulmonary

Last Updated: 6/8/23